4.7 Review

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases

Journal

JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 5, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/1756-8722-5-12

Keywords

ASXL1; Gene mutations; Myeloid diseases

Funding

  1. Inserm
  2. Institut Paoli-Calmettes
  3. Association pour la Recherche sur le Cancer
  4. Association Laurette Fugain

Ask authors/readers for more resources

The ASXL1 gene is one of the most frequently mutated genes in malignant myeloid diseases. The ASXL1 protein belongs to protein complexes involved in the epigenetic regulation of gene expression. ASXL1 mutations are found in myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). They are generally associated with signs of aggressiveness and poor clinical outcome. Because of this, a systematic determination of ASXL1 mutational status in myeloid malignancies should help in prognosis assessment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available